LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47 th Annual Global Healthcare Conference in Miami Beach, Fla....
– Delivered double-digit reported and constant-currency revenue growth – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance...
– Study demonstrates proximal hypoglossal nerve stimulation (pHGNS) yielded clinically significant responses and sustained improvements over time – First rigorous...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern...
– First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language – Next-generation,...
– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance,...